Neurogene Inc.
Neurogene Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 25.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 13, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 15, 2028 | Gene Therapy Study for Children With CLN5 Batten Disease | Trial Milestone | Phase 1/Phase 2 |
| December 15, 2029 | A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | Trial Milestone | Phase 3 |
Track NGNE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open NGNE in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.